, Bristol-Myers Squibb (BMS) UK and Ireland , Strategic Partnership and Early Asset Director ,
Sue Bailey is Strategic Partnership and Early Asset Director at Bristol-Myers Squibb (BMS) UK and Ireland as well as having some responsibility for Early Assets across Canada, Australia and the Nordic markets. Sue has 30 years oncology experience gained from both academia and industry and before transitioning to her current role, headed up the oncology medical team at BMS UK / Ireland. Prior to joining BMS 22 years ago, she gained a PhD from Cambridge/ Beatson Institute Glasgow and a postdoc from St Thomas' hospital, London and holds an MBA. Previous external positions held include Hon Secretary of the British Association of Cancer Research, Chair of the Association of the British Pharmaceutical Industry Cancer Group, industry representative on the Cancer Theme National Group of the NIHR, industry representative at House of Commons Select Committee review on cancer and she has supported work for the Bloodwise Trial Acceleration Program. Sue currently chairs the Industry Consultation Group for the national conference of the National Cancer Research Institute.